Edwards Lifesciences (NYSE:EW) Earns “Buy” Rating from BTIG Research

Edwards Lifesciences (NYSE:EW)‘s stock had its “buy” rating reaffirmed by equities researchers at BTIG Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $103.00 price objective on the medical research company’s stock. BTIG Research’s target price suggests a potential upside of 34.83% from the company’s previous close.

A number of other brokerages have also recently commented on EW. The Goldman Sachs Group reiterated a “buy” rating and set a $95.00 target price (down previously from $108.00) on shares of Edwards Lifesciences in a report on Wednesday. UBS Group reissued a “neutral” rating and issued a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Barclays reaffirmed an “overweight” rating and set a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Citigroup reissued a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Finally, Jefferies Financial Group set a $98.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $76.39 on Wednesday. The firm has a market capitalization of $44.33 billion, a PE ratio of 41.74, a P/E/G ratio of 3.03 and a beta of 0.94. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89. The firm’s 50-day simple moving average is $83.55 and its 200 day simple moving average is $81.10. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter last year, the business posted $0.59 earnings per share. The business’s revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 43,804 shares of company stock valued at $3,699,082 in the last ninety days. Company insiders own 1.29% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the business. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 3rd quarter valued at $25,000. Rosenberg Matthew Hamilton purchased a new stake in shares of Edwards Lifesciences in the second quarter worth about $28,000. True Wealth Design LLC grew its stake in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after buying an additional 259 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $28,000. Finally, Hilton Head Capital Partners LLC acquired a new position in Edwards Lifesciences during the 4th quarter worth approximately $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences News Roundup

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Analyst upgrades and reiterated buys lift longer‑term outlook — Wells Fargo raised its price target to $100 and moved to “overweight,” while BTIG and several other firms reiterated Buy ratings with ~$103 targets, supporting upside expectations. Article Title
• Positive Sentiment: Strong revenue growth and TAVR momentum highlighted on the earnings call — Management emphasized sustained Transcatheter Aortic Valve Replacement (TAVR) and other structural‑heart growth drivers; the company is leaning into growth after the quarter. Article Title
• Positive Sentiment: Options/contrarian take: some traders see the post‑earnings weakness as a buying opportunity — commentary suggests cleared uncertainty after results could support a tactical bullish trade. Article Title
• Neutral Sentiment: Mixed earnings print — Q4 revenue topped expectations and grew year‑over‑year, but EPS missed estimates. Revenue strength supports the growth narrative, while the EPS shortfall creates near‑term uncertainty. Article Title
• Neutral Sentiment: Sector context — Comparative coverage of healthcare earnings (AstraZeneca vs. Edwards vs. Zimmer Biomet) highlights macro/peer performance but is not specific to EW’s fundamentals. Article Title
• Negative Sentiment: Shareholder‑rights notice from Halper Sadeh LLC adds legal/uncertainty risk — a public call encouraging shareholders to contact the firm can prompt selling or increase perceived governance risk. Article Title

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.